PE20050470A1 - 5-arilpirimidinas como agentes anticancerigenos - Google Patents

5-arilpirimidinas como agentes anticancerigenos

Info

Publication number
PE20050470A1
PE20050470A1 PE2004000922A PE2004000922A PE20050470A1 PE 20050470 A1 PE20050470 A1 PE 20050470A1 PE 2004000922 A PE2004000922 A PE 2004000922A PE 2004000922 A PE2004000922 A PE 2004000922A PE 20050470 A1 PE20050470 A1 PE 20050470A1
Authority
PE
Peru
Prior art keywords
pyrimidin
chloro
compound
arylpyrimidines
cancer agents
Prior art date
Application number
PE2004000922A
Other languages
English (en)
Spanish (es)
Inventor
Nan Zhang
Semiramis Ayral-Kaloustian
Thai Nguyen
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20050470A1 publication Critical patent/PE20050470A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2004000922A 2003-09-24 2004-09-22 5-arilpirimidinas como agentes anticancerigenos PE20050470A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50548703P 2003-09-24 2003-09-24

Publications (1)

Publication Number Publication Date
PE20050470A1 true PE20050470A1 (es) 2005-10-03

Family

ID=34393022

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000922A PE20050470A1 (es) 2003-09-24 2004-09-22 5-arilpirimidinas como agentes anticancerigenos

Country Status (24)

Country Link
US (1) US7524849B2 (cg-RX-API-DMAC7.html)
EP (1) EP1663241B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007506746A (cg-RX-API-DMAC7.html)
KR (1) KR20060089215A (cg-RX-API-DMAC7.html)
CN (1) CN1871009A (cg-RX-API-DMAC7.html)
AR (1) AR045811A1 (cg-RX-API-DMAC7.html)
AT (1) ATE432077T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004275733A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0414736A (cg-RX-API-DMAC7.html)
CA (1) CA2539235A1 (cg-RX-API-DMAC7.html)
CO (1) CO5690592A2 (cg-RX-API-DMAC7.html)
DE (1) DE602004021269D1 (cg-RX-API-DMAC7.html)
EC (1) ECSP066457A (cg-RX-API-DMAC7.html)
GT (1) GT200400188A (cg-RX-API-DMAC7.html)
IL (1) IL174305A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06003207A (cg-RX-API-DMAC7.html)
NO (1) NO20061319L (cg-RX-API-DMAC7.html)
PA (1) PA8613201A1 (cg-RX-API-DMAC7.html)
PE (1) PE20050470A1 (cg-RX-API-DMAC7.html)
RU (1) RU2006107578A (cg-RX-API-DMAC7.html)
SA (1) SA04250303A (cg-RX-API-DMAC7.html)
TW (1) TW200512198A (cg-RX-API-DMAC7.html)
WO (1) WO2005030216A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200602386B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200637556A (en) * 2005-01-31 2006-11-01 Basf Ag Substituted 5-phenyl pyrimidines I in therapy
WO2006138180A1 (en) * 2005-06-13 2006-12-28 Wyeth Tubulin inhibitor and process for its preparation
CN101193884A (zh) 2005-06-13 2008-06-04 惠氏公司 微管蛋白抑制剂和其制备方法
US20110201496A1 (en) * 2006-03-27 2011-08-18 Joachim Rheinheimer Substituted 5-Hetaryl-4-Aminopyrimidines
CL2007002231A1 (es) * 2006-08-02 2008-04-11 Basf Ag Uso de compuestos derivados de 5-(het) arilpirimidina para combatir hongos daninos; compuestos derivados de 5-(het) arilpirimidina; agente fungicida; y agente farmaceutico.
AR064852A1 (es) * 2007-01-11 2009-04-29 Basf Ag Pirimidinas sustituidas en posicion 2
WO2009007187A1 (de) * 2007-07-09 2009-01-15 Basf Se Substituierte 5-hetarylpyrimidine
FI2699553T3 (fi) 2011-04-22 2024-01-24 Signal Pharm Llc Substituoituja diaminokarboksamidi- ja diaminokarbonitriilipyrimidiinejä, niiden koostumuksia ja niitä käyttäviä hoitomenetelmiä
EP3219207A1 (en) * 2012-09-19 2017-09-20 The Trustees Of The University Of Pennsylvania Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
US9513297B2 (en) 2014-12-16 2016-12-06 Signal Pharmaceuticals, Llc Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
KR102606253B1 (ko) 2014-12-16 2023-11-27 시그날 파마소티칼 엘엘씨 2-(tert-부틸아미노)-4-((1r,3r,4r)-3-하이드록시-4-메틸사이클로헥실아미노)-피리미딘-5-카복사마이드의 제형
WO2016123291A1 (en) 2015-01-29 2016-08-04 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
CA3208587A1 (en) 2015-07-24 2017-02-02 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
US11623927B2 (en) 2018-03-02 2023-04-11 The Trustees Of The University Of Pennsylvania Substituted [1,2,4]triazolo[1,5-a]pyrimidines for stabilizing microtubules
EP4052759A4 (en) * 2019-11-01 2023-12-20 Unimatec Co., Ltd. FLUORINE-CONTAINING PYRIMIDINE COMPOUND AND METHOD FOR THE PRODUCTION THEREOF
TW202132285A (zh) * 2019-11-13 2021-09-01 美商愛彼特生物製藥股份有限公司 經取代異吲哚啉基2,2’-聯嘧啶基化合物、其類似物及使用其之方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US147744A (en) * 1874-02-24 Improvement in locomotive-furnaces
US69242A (en) * 1867-09-24 Calvin pepper
US61889A (en) * 1867-02-05 Improvement in animal teaps
US116429A (en) * 1871-06-27 Improvement in dial-telegraph apparatus
US88096A (en) * 1869-03-23 t h a y e r
GB9700664D0 (en) 1997-01-14 1997-03-05 British Tech Group Anti-cancer agents
US6117876A (en) 1997-04-14 2000-09-12 American Cyanamid Company Fungicidal trifluorophenyl-triazolopyrimidines
EP1076053B1 (en) 1998-04-27 2006-11-29 Kumiai Chemical Industry Co., Ltd. 3-arylphenyl sulfide derivatives and insecticides and miticides
US6156925A (en) 1998-09-25 2000-12-05 American Cyanamid Company Process for the preparation of halogenated phenylmaloates
US5986135A (en) 1998-09-25 1999-11-16 American Cyanamid Company Fungicidal trifluoromethylalkylamino-triazolopyrimidines
HUP0300649A3 (en) 2000-06-13 2003-10-28 Basf Ag Fungicidal 5-phenyl substituted 2-(cyanoamino)pyrimidines, preparation and use thereof
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
CZ20032475A3 (cs) * 2001-03-15 2003-12-17 Basf Aktiengesellschaft 5-Fenylpyrimidiny, způsob jejich přípravy, meziprodukty pro jejich přípravu a jejich použití pro kontrolu škodlivých hub
ATE297390T1 (de) 2001-04-20 2005-06-15 Ciba Sc Holding Ag 4-amino-2-(2-pyridinyl)pyrimidine als mikrobizide wirksubstanzen
CN1312134C (zh) 2001-11-19 2007-04-25 巴斯福股份公司 5-苯基嘧啶化合物、包含它们的组合物、其制备方法及其用途
EP1504001B1 (de) 2002-02-21 2009-04-15 Basf Se 2-(2-pyridyl)-5-phenyl-6-aminopyrimidine, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen
JP2005520821A (ja) 2002-03-15 2005-07-14 チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド 4−アミノピリミジン及び表面の抗菌処理のためのその使用
MXPA05005477A (es) 2002-11-21 2005-07-25 Chiron Corp Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento del cancer.

Also Published As

Publication number Publication date
ECSP066457A (es) 2006-09-18
RU2006107578A (ru) 2007-10-27
CA2539235A1 (en) 2005-04-07
PA8613201A1 (es) 2005-11-25
EP1663241B1 (en) 2009-05-27
EP1663241A1 (en) 2006-06-07
IL174305A0 (en) 2008-02-09
TW200512198A (en) 2005-04-01
WO2005030216A1 (en) 2005-04-07
US20050075357A1 (en) 2005-04-07
GT200400188A (es) 2005-05-02
ATE432077T1 (de) 2009-06-15
JP2007506746A (ja) 2007-03-22
ZA200602386B (en) 2009-03-25
CO5690592A2 (es) 2006-10-31
AR045811A1 (es) 2005-11-16
KR20060089215A (ko) 2006-08-08
AU2004275733A1 (en) 2005-04-07
NO20061319L (no) 2006-04-20
CN1871009A (zh) 2006-11-29
US7524849B2 (en) 2009-04-28
MXPA06003207A (es) 2006-06-23
BRPI0414736A (pt) 2006-11-21
SA04250303A (ar) 2005-12-03
DE602004021269D1 (de) 2009-07-09

Similar Documents

Publication Publication Date Title
PE20050470A1 (es) 5-arilpirimidinas como agentes anticancerigenos
RU2356903C2 (ru) C-6 модифицированные индазолилпирролотриазины
RU2373209C2 (ru) Пирролотриазиновые соединения как ингибиторы киназ
RU2216545C2 (ru) Гетероарил-1-пиперидины и пиперазины, фармацевтическая композиция на их основе, способ лечения психозов и ослабления боли
RU2436776C2 (ru) ДИАРИЛАМИН-СОДЕРЖАЩИЕ СОЕДИНЕНИЯ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРОВ с-КIT
RU2437882C2 (ru) Производные имидазолидинона
PE20050020A1 (es) DERIVADOS 4-(2-OXO-2,3-DIHIDRO-1-H-IMIDAZO[4,5-b]PIRIDIN-1-IL)-N-(2-OXO-AZEPAN-3-IL)PIPERIDINIL-1-CARBOXAMIDA SUSTITUIDOS COMO ANTAGONISTAS DEL RECEPTOR CGRP
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
PE20081530A1 (es) Nuevos compuestos 617
PE20080677A1 (es) Inhibidores de pirrolotriazina cinaza
RU2436785C2 (ru) Гетеробициклические карбоксамиды в качестве ингибиторов киназ
PE20011291A1 (es) Combinacion sinergetica de derivados de benzodiazepina, agentes citotoxicos, citostaticos y antiproliferativos para el tratamiento del cancer
RU2006146070A (ru) Циннамидное соединение
PE20070108A1 (es) Control de parasitos en animales con derivados de n-[(feniloxi)fenil]-1,1,1-trifluorometansulfonamida y de n-[(fenilsulfanil)fenil]-1,1,1-trifluorometansulfonamida
JP2007505878A5 (cg-RX-API-DMAC7.html)
PE20091095A1 (es) Moduladores de gamma secretasa
JP2013533317A5 (cg-RX-API-DMAC7.html)
RU2008126391A (ru) Производные 1,5-замещенного индол-2-иламида
JP2009513575A5 (cg-RX-API-DMAC7.html)
PE20050670A1 (es) Agentes antimigrana heterociclicos
RU2000129161A (ru) Производное 1-[(1-замещенного-4-пиперидинил)метил]-4-пиперидина, способ его получения, фармацевтическая композиция, содержащая указанное соединение, и промежуточный продукт
PE20060150A1 (es) Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion
PE20040687A1 (es) Quinolinas sustituidas como antagonistas del receptor ccr5
JP2007505922A5 (cg-RX-API-DMAC7.html)
CN114430740A (zh) Egfr抑制剂、组合物及其制备方法

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed